EVT 801
Alternative Names: EVT-801Latest Information Update: 26 Aug 2025
At a glance
- Originator Sanofi
- Developer Evotec SE; Sanofi
- Class Alcohols; Alkanes; Alkynes; Amines; Aminopyridines; Antineoplastics; Ethers; Imidazoles; Ketones; Methyl ethers; Naphthyridines; Pyridones; Small molecules
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 26 Aug 2025 Chemical structure information added.
- 13 Jun 2025 Phase I development for Solid tumours is ongoing (Late-stage disease, Metastatic disease, Second-line therapy or greater) in France (PO)
- 23 Sep 2024 Kazia Therapeutics completes a Phase-I clinical trials in Solid tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater) in France (PO) before September 2024 (NCT05114668)